QDEL Stock Analysis: QuidelOrtho | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 729m USD | 12M Return: -51.6% | US2197981051 | Charts, Fundamentals & Technical Analysis

Clinical Chemistry, Immunoassays, Blood Typing, Molecular Diagnostics
Total Rating 16
Safety 61
Buy Signal -1.09
Health Care Supplies
Sub-Industry Rotation: +15.6
Market Cap: 729M
Avg Turnover: 28.8M
Risk 3d forecast
Volatility114%
VaR 5th Pctl17.3%
VaR vs Median-6.13%
Reward TTM
Sharpe Ratio-0.39
Rel. Str. IBD4.1
Rel. Str. Peer Group2.3 pctl
Character TTM
Beta2.213
Beta Downside2.194
Hurst Exponent0.439
Choppyness80.4%
Drawdowns 3y
Max DD86.80%
CAGR/Max DD-0.54
CAGR/Mean DD-0.84
EPS (Earnings per Share) EPS (Earnings per Share) of QDEL over the last years for every Quarter: "2021-09": 5.36, "2021-12": 7.29, "2022-03": 11.66, "2022-06": 2.34, "2022-09": 1.85, "2022-12": 1.76, "2023-03": 1.8, "2023-06": 0.26, "2023-09": 0.9, "2023-12": 1.17, "2024-03": 0.44, "2024-06": -0.07, "2024-09": 0.85, "2024-12": 0.63, "2025-03": 0.74, "2025-06": 0.12, "2025-09": 0.8, "2025-12": 0.46, "2026-03": -0.04, "2026-06": 0.13, "2026-09": 0.31,
EPS CAGR: -32.21%
EPS Trend: -87.0%
Last SUE: 0.50
Qual. Beats: 0
Revenue Revenue of QDEL over the last years for every Quarter: 2021-09: 509.8, 2021-12: 636.867, 2022-03: 1002.3, 2022-06: 613.4, 2022-09: 783.8, 2022-12: 866.5, 2023-03: 846.1, 2023-06: 665.1, 2023-09: 744, 2023-12: 742.6, 2024-03: 711, 2024-06: 637, 2024-09: 727.1, 2024-12: 707.8, 2025-03: 692.8, 2025-06: 613.9, 2025-09: 699.9, 2025-12: 723.6, 2026-03: 619.8, 2026-06: 630.9, 2026-09: 618.9,
Rev. CAGR: -3.98%
Rev. Trend: -95.5%
Last SUE: -0.25
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage
High Debt While Negative Cash Flow
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Choppy
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan -1.9% 9
Feb -5.5% 4
Mar +2.0% 4
Apr -5.4% 14
May +0.2% 0
Jun +3.7% 28
Jul +3.5% 14
Aug -0.3% 0
Sep -1.6% 0
Oct -6.5% 14
Nov +7.2% 9
Dec -0.8% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: QDEL QuidelOrtho

QuidelOrtho Corporation (NASDAQ: QDEL) is a diagnostic testing company that operates through four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The Labs unit provides clinical chemistry and immunoassay instruments and tests, along with disease monitoring and specialized diagnostic solutions. The Transfusion Medicine unit supplies immunohematology products for blood typing and donor screening instruments for infectious disease testing in blood and plasma. The Point of Care unit delivers rapid-result testing across various care settings, while the Molecular Diagnostics unit offers PCR thermocyclers, amplification systems, and sample-to-result instruments for syndromic infectious disease testing. The company was incorporated in 1979 and is headquartered in San Diego, California, with operations spanning North America, Europe, the Middle East, Africa, China, Japan, Asia Pacific, and Latin America.

QuidelOrtho sells its products through a direct sales force and a network of distributors, serving a broad range of customers including hospitals, clinical and reference laboratories, physician offices, urgent care clinics, blood banks, and retail outlets. As a small-cap healthcare supplies company, it operates in the in vitro diagnostics industry, which is characterized by ongoing demand for clinical testing driven by aging populations, infectious disease screening, and blood safety requirements. Its diversified business model spans hospital-based labs, donor centers, and over-the-counter settings, providing multiple channels of recurring revenue from consumable test kits and reagents.

Headlines to Watch Out For
  • Sofia respiratory test demand fluctuates with flu and COVID seasons
  • QuidelOrtho merger integration costs pressure near-term margins
  • Transfusion Medicine segment drives recurring hospital-based revenue
Piotroski VR-10 (Strict) 1.5
Net Income: -369.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.02 > 0.02 and ΔFCF/TA -1.29 > 1.0
NWC/Revenue: 14.61% < 20% (prev 22.06%; Δ -7.45% < -1%)
CFO/TA 0.00 > 3% & CFO 7.90m > Net Income -369.2m
Net Debt (3.10b) to EBITDA (326.9m): 9.47 < 3
Current Ratio: 1.36 > 1.5 & < 3
Outstanding Shares: last quarter (68.7m) vs 12m ago 1.03% < -2%
Gross Margin: 44.22% > 18% (prev 47.15%; Δ -2.93% > 0.5%)
Asset Turnover: 45.27% > 50% (prev 47.83%; Δ -2.56% > 0%)
Interest Coverage Ratio: -0.66 > 6 (EBIT TTM -134.8m / Interest Expense TTM 204.3m)
Altman Z'' 0.05
A: 0.07 (Total Current Assets 1.45b - Total Current Liabilities 1.07b) / Total Assets 5.78b
B: -0.21 (Retained Earnings -1.23b / Total Assets 5.78b)
C: -0.02 (EBIT TTM -134.8m / Avg Total Assets 5.73b)
D: 0.45 (Book Value of Equity 1.79b / Total Liabilities 3.99b)
Altman-Z'' = 0.05 = B
Beneish M -3.20
DSRI: 0.77 (Receivables 375.5m/513.0m, Revenue 2.59b/2.71b)
GMI: 1.07 (GM 47.15% / 44.22%)
AQI: 0.99 (AQ_t 0.49 / AQ_t-1 0.50)
SGI: 0.96 (Revenue 2.59b / 2.71b)
TATA: -0.07 (NI -369.2m - CFO 7.90m) / TA 5.78b)
Beneish M = -3.20 (Cap -4..+1) = AA
What is the price of QDEL shares?

As of November 17, 2026, the stock is trading at USD 10.21 with a total of 1,942,277 shares traded. Over the past week, the price has changed by -15.55%, over one month by -20.91%, over three months by -29.97% and over the past year by -51.61%.

Current recommended Stop Loss: 8.70 (which is 14.8% or 1.2 ATR below the current price).

Is QDEL a buy, sell or hold?

QuidelOrtho has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold QDEL.

  • StrongBuy: 1
  • Buy: 0
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the QDEL price?
Analysts Target Price 15 46.9%
QuidelOrtho (QDEL) - Fundamental Data Overview as of 14 November 2026
Market Cap USD = 728.7m (728.7m USD * 1.0 USD.USD)
P/E Forward = 9.5877
P/S = 0.281
P/B = 0.4564
P/EG = 2.0638
Revenue TTM = 2.59b USD
EBIT TTM = -134.8m USD
EBITDA TTM = 326.9m USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 424.4m USD (from shortTermDebt, last quarter)
Debt = 3.26b USD (from shortLongTermDebtTotal, last quarter) + Leases 179.0m
Net Debt = 3.10b USD (calculated: Debt 3.26b - CCE 166.4m)
Enterprise Value = 3.83b USD (728.7m + Debt 3.26b - CCE 166.4m)
Interest Coverage Ratio = -0.66 (Ebit TTM -134.8m / Interest Expense TTM 204.3m)
EV/FCF = -32.45x (Enterprise Value 3.83b / FCF TTM -117.9m)
FCF Yield = -3.08% (FCF TTM -117.9m / Enterprise Value 3.83b)
FCF Margin = -4.55% (FCF TTM -117.9m / Revenue TTM 2.59b)
Net Margin = -14.24% (Net Income TTM -369.2m / Revenue TTM 2.59b)
Gross Margin = 44.22% ((Revenue TTM 2.59b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 46.79% (prev 43.26%)
Tobins Q-Ratio = 0.66 (Enterprise Value 3.83b / Total Assets 5.78b)
Interest Expense / Debt = 6.26% (Interest Expense 204.3m / Debt 3.26b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -106.5m (EBIT -134.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.36 (Total Current Assets 1.45b / Total Current Liabilities 1.07b)
Debt / Equity = 1.82 (Debt 3.26b / totalStockholderEquity, last quarter 1.79b)
Debt / EBITDA = 9.47 (Net Debt 3.10b / EBITDA 326.9m)
 Debt / FCF = -26.27 (negative FCF - burning cash) (Net Debt 3.10b / FCF TTM -117.9m)
 Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.45% (Net Income -369.2m / Total Assets 5.78b)
RoE = -20.13% (Net Income TTM -369.2m / Total Stockholder Equity 1.83b)
RoCE = -3.10% (EBIT -134.8m / Capital Employed (Equity 1.83b + L.T.Debt 2.51b))
 RoIC = -2.13% (negative operating profit) (NOPAT -106.5m / Invested Capital 5.01b)
 WACC = 6.43% (E(728.7m)/V(3.99b) * Re(13.06%) + D(3.26b)/V(3.99b) * Rd(6.26%) * (1-Tc(0.21)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 96.95 | Cagr: 1.05%
 [DCF] Fair Price = unknown (Cash Flow -117.9m)
 EPS Correlation: -86.96 | EPS CAGR: -32.21% | SUE: 0.50 | # QB: 0
Revenue Correlation: -95.51 | Revenue CAGR: -3.98% | SUE: -0.25 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.06 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.67 | Chg30d=-13.93% | Revisions=-25% | GrowthEPS=-68.6% | GrowthRev=-7.7%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=-8.78% | Revisions=-40% | GrowthEPS=+97.4% | GrowthRev=-0.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)